Fig. 6: Dysregulated VCAM1 signaling is associated with impaired microglial infiltration into Aβ plaques in patients with AD.
From: The VCAM1–ApoE pathway directs microglial chemotaxis and alleviates Alzheimer’s disease pathology
a–c, Soluble VCAM1 (sVCAM1) level is elevated in the plasma of patients with AD and correlated with disease severity. a, sVCAM1 levels in the plasma of normal controls (NCs) and patients with AD (NC: n = 15; AD: n = 17; two-tailed Mann–Whitney test). b,c, Correlations between plasma levels of sVCAM1 and plasma p-Tau181 (b) (tau phosphorylated at threonine-181) and plasma NfL (c) (neurofilament light polypeptide) (n = 30 for panel b, n = 31 for panel c; linear regression). Dotted line indicates the 95% confidence interval of the regression line. d–f, Cerebrospinal fluid (CSF) sVCAM1 levels are inversely correlated with microglial infiltration into Aβ plaques. Representative images (d) and dot plot (e) showing the correlation between CSF sVCAM1 level and microglial infiltration into Aβ plaques in patients with AD (n = 26, linear regression). Dotted line indicates the 95% confidence interval of the regression line. Scale bar = 20 μm. f, Dot plot showing the correlations between CSF sVCAM1 level and microglial infiltration into Aβ plaques in patients with AD stratified by ApoE4 genotype. All data are mean ± s.e.m.
